HC Wainwright & Co. Assumes Odyssey Therapeutics at Buy, Announces Price Target of $40
Benzinga Newsdesk 5 hours ago
Analyst RatingsNewsInitiationPrice Target
HC Wainwright & Co. analyst Joseph Pantginis assumes Odyssey Therapeutics (NASDAQ:ODTX) with a Buy rating and announces Price Target of $40.
HC Wainwright & Co. analyst Joseph Pantginis assumes Odyssey Therapeutics (NASDAQ:ODTX) with a Buy rating and announces Price Target of $40.